Research Center, Centre Hospitalier de L'Université de Montréal (CRCHUM), 900 rue Saint-Denis, Montréal, QC, H2X0A9, Canada.
Faculty of Medicine and Health Sciences, Université de Sherbrooke, Longueuil, Canada.
AIDS Behav. 2020 Aug;24(8):2400-2408. doi: 10.1007/s10461-020-02800-w.
Recent studies have highlighted the efficacy of and willingness to use pre-exposure prophylaxis (PrEP) to prevent HIV infection among people who inject drugs (PWID), however knowledge of real-world applicability is limited. We aimed to quantify the real-world eligibility for HIV-PrEP among HIV-negative PWID in Montreal, Canada (n = 718). Eligibility was calculated according to US Centers for Disease Control and Prevention (CDC) guidelines and compared to risk of HIV acquisition according to the assessing the risk of contracting HIV (ARCH-IDU) risk screening tool. Over one-third of participants (37%) were eligible for HIV PrEP, with 1/3 of these eligible due to sexual risk alone. Half of participants were considered high risk of HIV acquisition according to ARCH-IDU, but there was poor agreement between the two measures. Although a large proportion of PWID were eligible for HIV-PrEP, better tools that are context- and location-informed are needed to identify PWID at higher risk of HIV acquisition.
最近的研究强调了在注射毒品者（PWID）中使用暴露前预防（PrEP）来预防 HIV 感染的效果和意愿，然而，实际应用的知识有限。我们旨在量化加拿大蒙特利尔 HIV 阴性 PWID 中 HIV-PrEP 的实际适用性（n=718）。根据美国疾病控制与预防中心（CDC）的指南计算了资格，并根据评估感染 HIV 的风险（ARCH-IDU）风险筛查工具比较了 HIV 获得的风险。超过三分之一的参与者（37%）有资格接受 HIV PrEP，其中 1/3 的人仅因性风险而有资格。根据 ARCH-IDU，一半的参与者被认为有 HIV 获得的高风险，但这两种措施之间的一致性很差。尽管很大一部分 PWID 有资格接受 HIV-PrEP，但需要更好的工具，这些工具应考虑到具体情况和地点，以确定 HIV 获得风险更高的 PWID。
